AMAG pays $674mm in cash and stock to buy Lumara Health
AMAG Pharmaceuticals Inc. (sells a therapy for kidney disease-related anemia and one for oral mucositis) will pay $600mm in cash and issue 3.2mm shares (valued at $74mm) to acquire Lumara Health Inc. (formerly KV Pharmaceutical) and its wholly owned subsidiaries, including key asset Makena (hydroxyprogesterone caproate). The transaction also includes up to $350mm in sales-based earn-outs.
- Generic Drugs
- Specialty Pharmaceuticals
- Controlled Release
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.